Potential application of antimicrobial peptides in the treatment of bacterial biofilm infections

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 67-84

  Strempel, Nikola ^a   Strehmel, Janine ^a   Overhage, Joerg ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Antibiofilm; Antimicrobial peptide; Biofilm infection; Cationic peptides; Chronic infection; Host defense peptide; Multidrug resistant bacteria

Indexed keywords

CATHELICIDIN; PEPTIDOMIMETIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOFILM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PLANKTON; ANIMAL; BACTERIAL INFECTIONS; DRUG DESIGN; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; BIOFILMS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; PREVALENCE;

EID: 84919754913     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905124312     Document Type: Article

References (230)

1. Gristina AG, Oga M, Webb LX, Hobgood CD. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 1985; 228: 990-3.
2. Hyde JA, Darouiche RO, Costerton JW. Strategies for prophylaxis against prosthetic valve endocarditis: a review article. J Heart Valve Dis 1998; 7: 316-26.
3. Bjarnsholt T, Kirketerp-Moller K, Jensen PO, et al. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 2008; 16: 2-10.
4. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112: 1466-77.
5. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
6. Siddiq DM, Darouiche RO. New strategies to prevent catheterassociated urinary tract infections. Nat Rev Urol 2012; 9: 305-14.
7. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002; 17: 47-56.
8. Davey ME, O'Toole G A. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 2000; 64: 847-67.
9. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
11. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
12. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010; 35: 322-32.
13. Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J, Handelsman J. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol 2010; 8: 251-9.
14. Hoiby N, Ciofu O, Johansen HK, et al. The clinical impact of bacterial biofilms. Int J Oral Sci 2011; 3: 55-65.
15. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13: 34-40.
16. de la Fuente-Nunez C, Korolik V, Bains M, et al. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother 2012; 56: 2696-704.
17. Siddiqui AR, Bernstein JM. Chronic wound infection: facts and controversies. Clin Dermatol 2010; 28: 519-26.
18. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 2002; 23: 183-9.
19. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
20. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
21. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-22.
22. Boman HG. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 1995; 13: 61-92.
23. Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 2012; 10: 243-54.
24. Afacan NJ, Yeung AT, Pena OM, Hancock RE. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des 2012; 18: 807-19.
25. Jacobsen AS, Jenssen H. Human cathelicidin LL-37 prevents bacterial biofilm formation. Future Med Chem 2012; 4: 1587-99.
26. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004; 172: 4987-94.
27. Mookherjee N, Hamill P, Gardy J, et al. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol Biosyst 2009; 5: 483-96.
28. Davidson DJ, Currie AJ, Reid GS, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146-56.
29. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
30. Nicolas P. Multifunctional host defense peptides: intracellulartargeting antimicrobial peptides. FEBS J 2009; 276: 6483-96.
31. Mok WW, Li Y. Therapeutic peptides: new arsenal against drug resistant pathogens. Curr Pharm Des 2013.
32. Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9: 62-75.
33. Lohner K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys 2009; 28: 105-16.
34. Laverty G, Gorman SP, Gilmore BF. The potential of antimicrobial peptides as biocides. Int J Mol Sci 2011; 12: 6566-96.
35. Fjell CD, Jenssen H, Hilpert K, et al. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J Med Chem 2009; 52: 2006-15.
36. Takahashi D, Shukla SK, Prakash O, Zhang G. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie 2010; 92: 1236-41.
37. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
38. Bessalle R, Haas H, Goria A, Shalit I, Fridkin M. Augmentation of the antibacterial activity of magainin by positive-charge chain extension. Antimicrob Agents Chemother 1992; 36: 313-7.
39. Matsuzaki K, Harada M, Funakoshi S, Fujii N, Miyajima K. Physicochemical determinants for the interactions of magainins 1 and 2 with acidic lipid bilayers. Biochim Biophys Acta 1991; 1063: 162-70.
40. Dathe M, Nikolenko H, Meyer J, Beyermann M, Bienert M. Optimization of the antimicrobial activity of magainin peptides by modification of charge. FEBS Lett 2001; 501: 146-50.
41. Strom MB, Haug BE, Skar ML, Stensen W, Stiberg T, Svendsen JS. The pharmacophore of short cationic antibacterial peptides. J Med Chem 2003; 46: 1567-70.
42. Wieprecht T, Dathe M, Beyermann M, et al. Peptide hydrophobicity controls the activity and selectivity of magainin 2 amide in interaction with membranes. Biochemistry 1997; 36: 6124-32.
43. Dathe M, Wieprecht T, Nikolenko H, et al. Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 1997; 403: 208-12.
44. Chen Y, Guarnieri MT, Vasil AI, Vasil ML, Mant CT, Hodges RS. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob Agents Chemother 2007; 51: 1398-406.
45. Malina A, Shai Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J 2005; 390: 695-702.
46. Laverty G, McLaughlin M, Shaw C, Gorman SP, Gilmore BF. Antimicrobial activity of short, synthetic cationic lipopeptides. Chem Biol Drug Des 2010; 75: 563-9.
47. Kondejewski LH, Jelokhani-Niaraki M, Farmer SW, et al. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J Biol Chem 1999; 274: 13181-92.
48. da Silva BR, de Freitas VA, Nascimento-Neto LG, et al. Antimicrobial peptide control of pathogenic microorganisms of the oral cavity: a review of the literature. Peptides 2012; 36: 315-21.
49. Gorr SU, Abdolhosseini M. Antimicrobial peptides and periodontal disease. J Clin Periodontol 2011; 38 Suppl 11: 126-41.
50. Gilmore K, Chen P, Leung KP. Anti-microbial peptides for plaque control and beyond. J Calif Dent Assoc 2009; 37: 779-88.
51. Harris F, Dennison SR, Phoenix DA. Anionic antimicrobial peptides from eukaryotic organisms. Curr Protein Pept Sci 2009; 10: 585-606.
52. Straus SK, Hancock RE. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta 2006; 1758: 1215-23.
53. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-47.
54. Kosciuczuk EM, Lisowski P, Jarczak J, et al. Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep 2012; 39: 10957-70.
55. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012; 280: 22-35.
56. Duplantier AJ, van Hoek ML. The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. Front Immunol 2013; 4: 143.
57. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008; 76: 4176-82.
58. Nagant C, Pitts B, Nazmi K, et al. Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments. Antimicrob Agents Chemother 2012; 56: 5698-708.
59. Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: Denantiomer of LL-37. Front Microbiol 2011; 2: 128.
60. Kai-Larsen Y, Luthje P, Chromek M, et al. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 2010; 6: e1001010.
61. Amer LS, Bishop BM, van Hoek ML. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem Biophys Res Commun 2010; 396: 246-51.
62. Hell E, Giske CG, Nelson A, Romling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol 2010; 50: 211-5.
63. Dean SN, Bishop BM, van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol 2011; 11: 114.
64. Bergsson G, Reeves EP, McNally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009; 183: 543-51.
65. Pompilio A, Scocchi M, Pomponio S, et al. Antibacterial and antibiofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 2011; 32: 1807-14.
66. Pompilio A, Crocetta V, Scocchi M, et al. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and antibiofilm activity of natural and designed alpha-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol 2012; 12: 145.
67. Cirioni O, Giacometti A, Ghiselli R, et al. Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 2006; 27: 2104-10.
68. Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2012; 56: 6366-71.
69. Steinstraesser L, Tack BF, Waring AJ, et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46: 1837-44.
70. Jacobsen F, Mohammadi-Tabrisi A, Hirsch T, et al. Antimicrobial activity of the recombinant designer host defence peptide Pnovispirin G10 in infected full-thickness wounds of porcine skin. J Antimicrob Chemother 2007; 59: 493-8.
71. Song Z, Wu H, Mygind P, et al. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother 2005; 49: 3868-74.
72. Ammons MC, Copie V. Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling 2013; 29: 443-55.
73. Hwang IS, Hwang JS, Hwang JH, et al. Synergistic effect and antibiofilm activity between the antimicrobial peptide coprisin and conventional antibiotics against opportunistic bacteria. Curr Microbiol 2013; 66: 56-60.
74. Minardi D, Ghiselli R, Cirioni O, et al. The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model. Peptides 2007; 28: 2293-8.
75. Schillaci D, Arizza V, Parrinello N, et al. Antimicrobial and antistaphylococcal biofilm activity from the sea urchin Paracentrotus lividus. J Appl Microbiol 2010; 108: 17-24.
76. Cirioni O, Giacometti A, Ghiselli R, et al. Citropin 1. 1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 2006; 27: 1210-6.
77. Zhang R, Zhou M, Wang L, et al. Phylloseptin-1 (PSN-1) from Phyllomedusa sauvagei skin secretion: a novel broad-spectrum antimicrobial peptide with antibiofilm activity. Mol Immunol 2010; 47: 2030-7.
78. Dennison SR, Morton LH, Shorrocks AJ, Harris F, Phoenix DA. A study on the interactions of Aurein 2. 5 with bacterial membranes. Colloids Surf B Biointerfaces 2009; 68: 225-30.
79. Choi H, Lee DG. Antimicrobial peptide pleurocidin synergizes with antibiotics through hydroxyl radical formation and membrane damage, and exerts antibiofilm activity. Biochim Biophys Acta 2012; 1820: 1831-8.
80. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC. Human defensins. J Mol Med (Berl) 2005; 83: 587-95.
81. Zhu C, Tan H, Cheng T, et al. Human beta-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation. J Surg Res 2013; 183: 204-13.
82. Huang Q, Yu HJ, Liu GD, et al. Comparison of the effects of human beta-defensin 3, vancomycin, and clindamycin on Staphylococcus aureus biofilm formation. Orthopedics 2012; 35: e53-60.
83. Cotter PD, Ross RP, Hill C. Bacteriocins-a viable alternative to antibiotics? Nat Rev Microbiol 2013; 11: 95-105.
84. Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol 2012; 12: 545-50.
85. Michalopoulos A, Falagas ME. Colistin and polymyxin B in critical care. Crit Care Clin 2008; 24: 377-91, x.
86. Azzopardi EA, Boyce DE, Thomas DW, Dickson WA. Colistin in burn intensive care: back to the future? Burns 2013; 39: 7-15.
87. Antoniu SA, Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin Drug Deliv 2012; 9: 333-42.
88. Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010; 202: 1585-92.
89. Marumo K, Komukai D, Hirose M, et al. Evaluation in vitro of the efficacy of colistin methanesulfonate against biofilm-forming multidrug-resistant Pseudomonas aeruginosa (MDRP). J Infect Chemother 2013; 19: 348-51.
90. Wu K, Yau YC, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2013; 57: 1546-8.
91. Ozbek B, Mataraci E. In vitro effectiveness of colistin, tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains. J Antimicrob Chemother 2013; 68: 827-30.
92. Volkow-Fernandez P, Rodriguez CF, Cornejo-Juarez P. Intravesical colistin irrigation to treat multidrug-resistant Acinetobacter baumannii urinary tract infection: a case report. J Med Case Rep 2012; 6: 426.
93. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
94. Hinsa SM, Espinosa-Urgel M, Ramos JL, O'Toole GA. Transition from reversible to irreversible attachment during biofilm formation by Pseudomonas fluorescens WCS365 requires an ABC transporter and a large secreted protein. Mol Microbiol 2003; 49: 905-18.
95. Zhu X, Liu W, Lametsch R, et al. Phenotypic, proteomic, and genomic characterization of a putative ABC-transporter permease involved in Listeria monocytogenes biofilm formation. Foodborne Pathog Dis 2011; 8: 495-501.
96. Hou S, Zhou C, Liu Z, et al. Antimicrobial dendrimer active against Escherichia coli biofilms. Bioorg Med Chem Lett 2009; 19: 5478-81.
97. Hou S, Liu Z, Young AW, Mark SL, Kallenbach NR, Ren D. Effects of Trp-and Arg-containing antimicrobial-peptide structure on inhibition of Escherichia coli planktonic growth and biofilm formation. Appl Environ Microbiol 2010; 76: 1967-74.
98. Chen X, Zhang M, Zhou C, Kallenbach NR, Ren D. Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides. Appl Environ Microbiol 2011; 77: 4878-85.
99. Eckert R, Brady KM, Greenberg EP, et al. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 2006; 50: 3833-8.
100. Hofmann CM, Bednar KJ, Anderson JM, Marchant RE. Disruption of Staphylococcus epidermidis biofilm formation using a targeted cationic peptide. J Biomed Mater Res A 2012; 100: 1061-7.
101. Menousek J, Mishra B, Hanke ML, Heim CE, Kielian T, Wang G. Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300. Int J Antimicrob Agents 2012; 39: 402-6.
102. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta 2009; 1788: 1582-92.
103. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of P. aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-70.
104. Leszczynska K, Namiot A, Fein DE, et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol 2009; 9: 187.
105. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother 2007; 60: 535-45.
106. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 2008; 62: 329-35.
107. Nagant C, Feng Y, Lucas B, Braeckmans K, Savage P, Dehaye JP. Effect of a low concentration of a cationic steroid antibiotic (CSA-13) on the formation of a biofilm by Pseudomonas aeruginosa. J Appl Microbiol 2011; 111: 763-72.
108. Leszczynska K, Namiot A, Cruz K, et al. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections. J Appl Microbiol 2011; 110: 229-38.
109. Nagant C, Pitts B, Stewart PS, Feng Y, Savage PB, Dehaye JP. Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa. Microbiologyopen 2013; 2: 318-25.
110. Kapoor R, Wadman MW, Dohm MT, Czyzewski AM, Spormann AM, Barron AE. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011; 55: 3054-7.
111. Liu Y, Knapp KM, Yang L, Molin S, Franzyk H, Folkesson A. High in vitro antimicrobial activity of beta-peptoid-peptide hybrid oligomers against planktonic and biofilm cultures of Staphylococcus epidermidis. Int J Antimicrob Agents 2013; 41: 20-7.
112. Koprivnjak T, Peschel A. Bacterial resistance mechanisms against host defense peptides. Cell Mol Life Sci 2011; 68: 2243-54.
113. Gruenheid S, Le Moual H. Resistance to antimicrobial peptides in Gram-negative bacteria. FEMS Microbiol Lett 2012; 330: 81-9.
114. Sieprawska-Lupa M, Mydel P, Krawczyk K, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureusderived proteinases. Antimicrob Agents Chemother 2004; 48: 4673-9.
115. Belas R, Manos J, Suvanasuthi R. Proteus mirabilis ZapA metalloprotease degrades a broad spectrum of substrates, including antimicrobial peptides. Infect Immun 2004; 72: 5159-67.
116. Kooi C, Sokol PA. Burkholderia cenocepacia zinc metalloproteases influence resistance to antimicrobial peptides. Microbiology 2009; 155: 2818-25.
117. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002; 46: 157-68.
118. Vuong C, Voyich JM, Fischer ER, et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 2004; 6: 269-75.
119. Kocianova S, Vuong C, Yao Y, et al. Key role of poly-gamma-DLglutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 2005; 115: 688-94.
120. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004; 72: 7107-14.
121. Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosisderived Pseudomonas aeruginosa. J Antimicrob Chemother 1988; 22: 667-74.
122. Chan C, Burrows LL, Deber CM. Helix induction in antimicrobial peptides by alginate in biofilms. J Biol Chem 2004; 279: 38749-54.
123. Kuo HH, Chan C, Burrows LL, Deber CM. Hydrophobic interactions in complexes of antimicrobial peptides with bacterial polysaccharides. Chem Biol Drug Des 2007; 69: 405-12.
124. Pedersen SS, Kharazmi A, Espersen F, Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 1990; 58: 3363-8.
125. Fey PD, Olson ME. Current concepts in biofilm formation of Staphylococcus epidermidis. Future Microbiol 2010; 5: 917-33.
126. Bader MW, Sanowar S, Daley ME, et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 2005; 122: 461-72.
127. Farris C, Sanowar S, Bader MW, Pfuetzner R, Miller SI. Antimicrobial peptides activate the Rcs regulon through the outer membrane lipoprotein RcsF. J Bacteriol 2010; 192: 4894-903.
128. Gunn JS, Lim KB, Krueger J, et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998; 27: 1171-82.
129. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-17.
130. McPhee JB, Bains M, Winsor G, et al. Contribution of the PhoPPhoQ and PmrA-PmrB two-component regulatory systems to Mg2+-induced gene regulation in Pseudomonas aeruginosa. J Bacteriol 2006; 188: 3995-4006.
131. Gooderham WJ, Gellatly SL, Sanschagrin F, et al. The sensor kinase PhoQ mediates virulence in Pseudomonas aeruginosa. Microbiology 2009; 155: 699-711.
132. Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PsrA in Pseudomonas aeruginosa. J Bacteriol 2008; 190: 5624-34.
133. Fernandez L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock RE. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS. Antimicrob Agents Chemother 2012; 56: 6212-22.
134. Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 2010; 54: 3372-82.
135. Cummins J, Reen FJ, Baysse C, Mooij MJ, O'Gara F. Subinhibitory concentrations of the cationic antimicrobial peptide colistin induce the pseudomonas quinolone signal in Pseudomonas aeruginosa. Microbiology 2009; 155: 2826-37.
136. Tzeng YL, Ambrose KD, Zughaier S, et al. Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol 2005; 187: 5387-96.
137. Shafer WM, Qu X, Waring AJ, Lehrer RI. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998; 95: 1829-33.
138. Bengoechea JA, Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000; 37: 67-80.
139. Rieg S, Huth A, Kalbacher H, Kern WV. Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps. Int J Antimicrob Agents 2009; 33: 174-6.
140. Zou Y, Woo J, Ahn J. Cellular and molecular responses of Salmonella Typhimurium to antimicrobial-induced stresses during the planktonic-to-biofilm transition. Lett Appl Microbiol 2012; 55: 274-82.
141. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68: 223-40.
142. Berditsch M, Afonin S, Vladimirova T, Wadhwani P, Ulrich AS. Antimicrobial Peptides can Enhance the Risk of Persistent Infections. Front Immunol 2012; 3: 222.
143. Napier BA, Burd EM, Satola SW, et al. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio 2013; 4: e00021-13.
144. Fjell CD, Hiss JA, Hancock RE, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2012; 11: 37-51.
145. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE. Highthroughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 2005; 23: 1008-12.
146. Hilpert K, Elliott MR, Volkmer-Engert R, et al. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem Biol 2006; 13: 1101-7.
147. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4: 65-74.
148. Simsek O, Akkoc N, Con AH, Ozcelik F, Saris PE, Akcelik M. Continuous nisin production with bioengineered Lactococcus lactis strains. J Ind Microbiol Biotechnol 2009; 36: 863-71.
149. de Arauz LJ, Jozala AF, Mazzola PG, Vessoni Penna TC. Nisin biotechnological production and application: a review. Trends in Food Science & Technology 2009; 20: 146-154.
150. Bommarius B, Jenssen H, Elliott M, et al. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 2010; 31: 1957-65.
151. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WH. Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorganic & Medicinal Chemistry Letters 1994; 4: 2657-2662.
152. Reymond JL, Bergmann M, Darbre T. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem Soc Rev 2013; 42: 4814-22.
153. Radzishevsky IS, Rotem S, Zaknoon F, Gaidukov L, Dagan A, Mor A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob Agents Chemother 2005; 49: 2412-20.
154. Kindrachuk J, Scruten E, Attah-Poku S, et al. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers 2011; 96: 14-24.
155. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 2003; 4: 339-56.
156. Hedstrom L. Enzyme Specificity and Selectivity. In: ed. eds., eLS. John Wiley & Sons, Ltd 2001.
157. Chennupati SK, Chiu AG, Tamashiro E, et al. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy 2009; 23: 46-51.
158. Roche ED, Renick PJ, Tetens SP, Carson DL. A model for evaluating topical antimicrobial efficacy against methicillinresistant Staphylococcus aureus biofilms in superficial murine wounds. Antimicrob Agents Chemother 2012; 56: 4508-10.
159. Melo MN, Ferre R, Castanho MA. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol 2009; 7: 245-50.
160. Park SC, Park Y, Hahm KS. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci 2011; 12: 5971-92.
161. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr Med Chem 2011; 18: 256-79.
162. Orlando F, Ghiselli R, Cirioni O, et al. BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. Peptides 2008; 29: 1118-1123.
163. Ghiselli R, Giacometti A, Cirioni O, et al. Pretreatment with the protegrin IB-367 affects Gram-positive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. JPEN J Parenter Enteral Nutr 2007; 31: 463-8.
164. Liu MC, Lin SB, Chien HF, et al. 10 '(Z), 13 '(E)-Heptadecadienylhydroquinone Inhibits Swarming and Virulence Factors and Increases Polymyxin B Susceptibility in Proteus mirabilis. Plos One 2012; 7.
165. Mobley HL, Belas R. Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol 1995; 3: 280-4.
166. Coker C, Poore CA, Li X, Mobley HL. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect 2000; 2: 1497-505.
167. Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 2008; 21: 26-59.
168. Sud IJ, Feingold DS. Mechanism of polymyxin B resistance in Proteus mirabilis. J Bacteriol 1970; 104: 289-94.
169. Klausen M, Aaes-Jorgensen A, Molin S, Tolker-Nielsen T. Involvement of bacterial migration in the development of complex multicellular structures in Pseudomonas aeruginosa biofilms. Mol Microbiol 2003; 50: 61-8.
170. Balaban N, Gov Y, Giacometti A, et al. A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant staphylococci. Antimicrob Agents Chemother 2004; 48: 2544-50.
171. Mor A, Hani K, Nicolas P. The vertebrate peptide antibiotics dermaseptins have overlapping structural features but target specific microorganisms. J Biol Chem 1994; 269: 31635-41.
172. Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother 2002; 46: 689-94.
173. Novick RP, Ross HF, Figueiredo AMS, Abramochkin G, Muir T. Activation and Inhibition of the Staphylococcal AGR System. Science 2000; 287: 391.
174. Gov Y, Bitler A, Dell'Acqua G, Torres JV, Balaban N. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 2001; 22: 1609-20.
175. Balaban N, Goldkorn T, Gov Y, et al. Regulation of Staphylococcus aureus pathogenesis via target of RNAIIIactivating Protein (TRAP). J Biol Chem 2001; 276: 2658-67.
176. Shaw LN, Jonsson IM, Singh VK, Tarkowski A, Stewart GC. Inactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureus. Infect Immun 2007; 75: 4519-27.
177. Tsang LH, Daily ST, Weiss EC, Smeltzer MS. Mutation of traP in Staphylococcus aureus has no impact on expression of agr or biofilm formation. Infect Immun 2007; 75: 4528-33.
178. Adhikari RP, Arvidson S, Novick RP. A nonsense mutation in agrA accounts for the defect in agr expression and the avirulence of Staphylococcus aureus 8325-4 traP:: kan. Infect Immun 2007; 75: 4534-40.
179. Mayville P, Ji G, Beavis R, et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc Natl Acad Sci USA 1999; 96: 1218-23.
180. Otto M. Quorum-sensing control in Staphylococci-a target for antimicrobial drug therapy? FEMS Microbiol Lett 2004; 241: 135-41.
181. Costa F, Carvalho IF, Montelaro RC, Gomes P, Martins MC. Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater 2011; 7: 1431-40.
182. Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev 2006; 35: 780-9.
183. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-72.
184. Jorge P, Lourenco A, Pereira MO. New trends in peptide-based anti-biofilm strategies: a review of recent achievements and bioinformatic approaches. Biofouling 2012; 28: 1033-61.
185. Onaizi SA, Leong SS. Tethering antimicrobial peptides: current status and potential challenges. Biotechnol Adv 2011; 29: 67-74.
186. Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 2002; 46: 741-9.
187. Etienne O, Picart C, Taddei C, et al. Multilayer polyelectrolyte films functionalized by insertion of defensin: a new approach to protection of implants from bacterial colonization. Antimicrob Agents Chemother 2004; 48: 3662-9.
188. Shukla A, Fleming KE, Chuang HF, et al. Controlling the release of peptide antimicrobial agents from surfaces. Biomaterials 2010; 31: 2348-57.
189. Glinel K, Thebault P, Humblot V, Pradier CM, Jouenne T. Antibacterial surfaces developed from bio-inspired approaches. Acta Biomater 2012; 8: 1670-84.
190. Humblot V, Yala JF, Thebault P, et al. The antibacterial activity of Magainin I immobilized onto mixed thiols Self-Assembled Monolayers. Biomaterials 2009; 30: 3503-12.
191. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449-53.
192. Wallace BA. Structure of gramicidin A. Biophys J 1986; 49: 295-306.
193. Yala JF, Thebault P, Hequet A, Humblot V, Pradier CM, Berjeaud JM. Elaboration of antibiofilm materials by chemical grafting of an antimicrobial peptide. Appl Microbiol Biotechnol 2011; 89: 623-34.
194. Gao G, Lange D, Hilpert K, et al. The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides. Biomaterials 2011; 32: 3899-909.
195. Salwiczek M, Qu Y, Gardiner J, et al. Emerging rules for effective antimicrobial coatings. Trends Biotechnol 2013.
196. Gabriel M, Nazmi K, Veerman EC, Nieuw Amerongen AV, Zentner A. Preparation of LL-37-grafted titanium surfaces with bactericidal activity. Bioconjug Chem 2006; 17: 548-50.
197. Cho WM, Joshi BP, Cho H, Lee KH. Design and synthesis of novel antibacterial peptide-resin conjugates. Bioorg Med Chem Lett 2007; 17: 5772-6.
198. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
199. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7: 391-7.
200. Eriksen KR. ["Celbenin"-resistant staphylococci]. Ugeskr Laeger 1961; 123: 384-6.
201. Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000; 19: 1163-6.
202. Campoccia D, Montanaro L, Speziale P, Arciola CR. Antibioticloaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials 2010; 31: 6363-77.
203. Zhao L, Chu PK, Zhang Y, Wu Z. Antibacterial coatings on titanium implants. J Biomed Mater Res B Appl Biomater 2009; 91: 470-80.
204. Wegener KL, Wabnitz PA, Carver JA, et al. Host defence peptides from the skin glands of the Australian blue mountains tree-frog Litoria citropa. Solution structure of the antibacterial peptide citropin 1. 1. Eur J Biochem 1999; 265: 627-37.
205. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 2003; 47: 2804-9.
206. Falla TJ, Karunaratne DN, Hancock RE. Mode of action of the antimicrobial peptide indolicidin. J Biol Chem 1996; 271: 19298-303.
207. Kanthawong S, Bolscher JG, Veerman EC, et al. Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei. Int J Antimicrob Agents 2012; 39: 39-44.
208. Molhoek EM, van Dijk A, Veldhuizen EJ, Haagsman HP, Bikker FJ. A cathelicidin-2-derived peptide effectively impairs Staphylococcus epidermidis biofilms. Int J Antimicrob Agents 2011; 37: 476-9.
209. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-5.
210. Ammons MC, Ward LS, Fisher ST, Wolcott RD, James GA. In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol. Int J Antimicrob Agents 2009; 33: 230-6.
211. Kamiya H, Ehara T, Matsumoto T. Inhibitory effects of lactoferrin on biofilm formation in clinical isolates of Pseudomonas aeruginosa. J Infect Chemother 2012; 18: 47-52.
212. Ochoa TJ, Noguera-Obenza M, Cleary TG. Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Exp Med Biol 2004; 554: 463-6.
213. Ochoa TJ, Brown EL, Guion CE, Chen JZ, McMahon RJ, Cleary TG. Effect of lactoferrin on enteroaggregative E. coli (EAEC). Biochem Cell Biol 2006; 84: 369-76.
214. Caraher EM, Gumulapurapu K, Taggart CC, Murphy P, McClean S, Callaghan M. The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms. J Antimicrob Chemother 2007; 60: 546-54.
215. Lee E, Kim JK, Shin S, et al. Insight into the antimicrobial activities of coprisin isolated from the dung beetle, Copris tripartitus, revealed by structure-activity relationships. Biochim Biophys Acta 2013; 1828: 271-83.
216. Jass J, Lappin-Scott HM. The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms. J Antimicrob Chemother 1996; 38: 987-1000.
217. Trafny EA. Susceptibility of adherent organisms from Pseudomonas aeruginosa and Staphylococcus aureus strains isolated from burn wounds to antimicrobial agents. Int J Antimicrob Agents 1998; 10: 223-8.
218. Tote K, Berghe DV, Deschacht M, de Wit K, Maes L, Cos P. Inhibitory efficacy of various antibiotics on matrix and viable mass of Staphylococcus aureus and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2009; 33: 525-31.
219. Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 2012; 56: 2683-90.
220. Flemming K, Klingenberg C, Cavanagh JP, et al. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J Antimicrob Chemother 2009; 63: 136-45.
221. Kharidia R, Liang JF. The activity of a small lytic peptide PTP-7 on Staphylococcus aureus biofilms. J Microbiol 2011; 49: 663-8.
222. Bucki R, Leszczynska K, Byfield FJ, et al. Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. Antimicrob Agents Chemother 2010; 54: 2525-33.
223. Johansson EM, Crusz SA, Kolomiets E, et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem Biol 2008; 15: 1249-57.
224. Pettit RK, Weber CA, Lawrence SB, Pettit GR, Kean MJ, Cage GD. In vivo activity of anprocide alone, and in vitro activity in combination with conventional antibiotics against Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Med Microbiol 2009; 58: 1203-6.
225. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 2013; 57: 1421-7.
226. Jones EA, McGillivary G, Bakaletz LO. Extracellular DNA within a nontypeable Haemophilus influenzae-induced biofilm binds human beta defensin-3 and reduces its antimicrobial activity. J Innate Immun 2013; 5: 24-38.
227. Zhu C, He N, Cheng T, et al. Ultrasound-targeted microbubble destruction enhances human beta-defensin 3 activity against antibiotic-resistant Staphylococcus biofilms. Inflammation 2013.
228. Ammons MC, Ward LS, James GA. Anti-biofilm efficacy of a lactoferrin/xylitol wound hydrogel used in combination with silver wound dressings. Int Wound J 2011; 8: 268-73.
229. Alves FR, Silva MG, Rocas IN, Siqueira JF, Jr. Biofilm biomass disruption by natural substances with potential for endodontic use. Braz Oral Res 2013; 27: 20-5.
230. Burton E, Gawande PV, Yakandawala N, et al. Antibiofilm activity of GlmU enzyme inhibitors against catheter-associated uropathogens. Antimicrob Agents Chemother 2006; 50: 1835-40.